医学
可欣
PCSK9
前蛋白转化酶
胆固醇
临床试验
药理学
脂蛋白
他汀类
Evolocumab公司
疾病
药方
内科学
低密度脂蛋白受体
载脂蛋白A1
出处
期刊:Cardiology in Review
[Ovid Technologies (Wolters Kluwer)]
日期:2022-01-31
卷期号:31 (3): 155-161
被引量:1
标识
DOI:10.1097/crd.0000000000000441
摘要
Reduction in low-density lipoprotein cholesterol levels is the cornerstone of treatment and prevention of atherosclerotic cardiovascular diseases. Currently, high-intensity statins are being used as the first-line therapy to lower low-density lipoprotein cholesterol levels, as they improve the prognosis of patients with atherosclerotic cardiovascular disease and those in high-risk groups. However, in some patients, the expected reduction in cholesterol is not achieved despite aggressive treatment with statins. Moreover, some patients cannot tolerate the dosage or show poor response or compliance to statins. Therefore, combination therapies with statins and other medications should be considered. Recently, several clinical trials have shown that the use of proprotein convertase subtilisin/kexin type 9 inhibitors with or without statins and/or other lipid-lowering drugs can significantly reduce low-density lipoprotein cholesterol levels, sometimes to extremely low levels. Therefore, to facilitate appropriate prescription of these new lipid-lowering drugs, we systemically evaluated the safety issues associated with these inhibitors and extremely low low-density lipoprotein cholesterol levels.
科研通智能强力驱动
Strongly Powered by AbleSci AI